ArticleCancer medicine2022
Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pooled it
- ASO Author Reflections: From Blood Pressure Control to Tumor Risk: Genetic Clues Linking Antihypertensive Drug Targets to Urological Tumors.Annals of surgical oncology · 2026Article
- Exploring the Associations and Mechanisms Between Antihypertensive Drugs and Urological Tumors: Insights from a Mendelian Randomization Study.Annals of surgical oncology · 2026Article
- Development and Deployment of a Machine Learning Model to Triage the Use of Prostate MRI (ProMT-ML) in Patients With Suspected Prostate Cancer.Journal of magnetic resonance imaging : JMRI · 2026Article
- Racial disparities in the receipt of therapies for cancer, hypertension, and diabetes, and in mortality in a large population-based cohort of older men with prostate cancer.Ethnicity & health · 2025Article
- Life's essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants.BMC cancer · 2025Article
- Improving drug repositioning with negative data labeling using large language models.Journal of cheminformatics · 2025Article
- Article
- Amiloride Sensitizes Prostate Cancer Cells to the Reversible Tyrosine Kinase Inhibitor Lapatinib by Modulating ERBB3 Subcellular Localization.Research square · 2024Article
- Article
- Association of diastolic and systolic blood pressure with depression: a cross-sectional study from NHANES 2005-2018.Frontiers in psychiatry · 2024Article
- Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.Current cardiology reports · 2023Review
- Expression of miR-24-1-5p in Tumor Tissue Influences Prostate Cancer Recurrence: The PROCA-Cancers · 2022Article
- Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study.Cancer medicine · 2022Article
- Design and Implementation of Taizhou Integrated Prostate Screening.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation has been linked to prostate cancer and hypertension, but it remains equivocal whether elevated blood pressure (BP) influence prostate cancer risk and survival.
methodUsing Cox regression models, we examined the association between prediagnostic BP and prostate cancer risk among 12,271 men participating in the Prostate Cancer throughout life (PROCA-life) study. Systolic and diastolic BP were measured. A total of 811 men developed prostate cancer, and followed for additional 7.1 years, and we studied the association between prediagnostic BP and overall mortality among patients with prostate cancer.
resultsMen (>45 years) with a systolic BP >150 mmHg had a 35% increased risk of prostate cancer compared with men with a normal systolic BP (<130 mmHg) (HR 1.35, 95% CI 1.08-1.69). Among patients with prostate cancer, men with systolic BP >150 mmHg had a 49% increased overall mortality compared with men with a normal systolic BP (HR 1.49, 1.06-2.01). Among patients with prostate cancer treated with curative intent, those with a high diastolic BP (>90 mmHg) had a threefold increase in overall mortality risk (HR 3.01, 95% CI 1.40-6.46) compared with patients with a normal diastolic BP (<80 mmHg).
conclusionOur results support that systolic and diastolic BP are important factors when balancing disease management in patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.